keyword
MENU ▼
Read by QxMD icon Read
search

Dyslipidemia, statins,

keyword
https://www.readbyqxmd.com/read/28726432/-news-in-the-treatment-of-hypertension-and-dyslipidemia
#1
Jan Václavík
These review article presents the results of major recent studies in cardiovascular prevention. HOPE-3 study showed that people with medium cardiovascular risk who have not experienced a cardiovascular event, and have normal blood pressure, benefit from deploying a statin, and in the presence of hypertension benefit from deploying a combination of a statin and antihypertensive drugs. Studies evaluating genetic predisposition brought new evidence that both LDL cholesterol and systolic blood pressure are independent and multiplicative causal risk factors for cardiovascular events...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/28721148/association-of-moderate-aerobic-exercise-and-rho-associated-kinase-2-concentration-in-subjects-with-dyslipidemia
#2
Huadong Bai, Jingchun Sun, Guiying Du, Fengjun Jiao
INTRODUCTION: Dyslipidemia is associated with increased rho-associated kinase 2 (ROCK2) concentration. Whether moderate aerobic exercise could attenuate leukocyte ROCK2 concentration is unknown. MATERIAL AND METHODS: One hundred subjects with dyslipidemia and without statin treatment were enrolled and assigned to exercise and control groups. In the exercise group, at least 30 min of moderate aerobic exercise per day 5 times weekly was recommended. In the control group, participants were recommended to undertake exercise of the same intensity as the exercise group but not mandatorily...
June 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/28717233/effect-of-ldl-cholesterol-statins-and-presence-of-mutations-on-the-prevalence-of-type-2-diabetes-in-heterozygous-familial-hypercholesterolemia
#3
Elisenda Climent, Sofía Pérez-Calahorra, Victoria Marco-Benedí, Nuria Plana, Rosa Sánchez, Emilio Ros, Juan F Ascaso, Jose Puzo, Fátima Almagro, Carlos Lahoz, Fernando Civeira, Juan Pedro-Botet
Patients with heterozygous familial hypercholesterolemia (HeFH) have been reported to be less vulnerable to type 2 diabetes mellitus (T2DM), although the mechanism is unknown. The aims of the present study were to assess the effects of low density lipoprotein (LDL) cholesterol concentration and the presence of FH-causing mutations on T2DM prevalence in HeFH. Data were collected from the Dyslipidemia Registry of the Spanish Arteriosclerosis Society. Inclusion criteria were definite or probable HeFH in patients aged ≥18 years...
July 17, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28699974/cardiovascular-risk-stratification-and-statin-eligibility-based-on-the-brazilian-vs-north-american-guidelines-on-blood-cholesterol-management
#4
Fernando Henpin Yue Cesena, Antonio Gabriele Laurinavicius, Viviane A Valente, Raquel D Conceição, Raul D Santos, Marcio S Bittencourt
Background: The best way to select individuals for lipid-lowering treatment in the population is controversial. Objective: In healthy individuals in primary prevention: to assess the relationship between cardiovascular risk categorized according to the V Brazilian Guideline on Dyslipidemia and the risk calculated by the pooled cohort equations (PCE); to compare the proportion of individuals eligible for statins, according to different criteria. Methods: In individuals aged 40-75 years consecutively submitted to routine health assessment at one single center, four criteria of eligibility for statin were defined: BR-1, BR-2 (LDL-c above or at least 30 mg/dL above the goal recommended by the Brazilian Guideline, respectively), USA-1 and USA-2 (10-year risk estimated by the PCE ≥ 5...
June 2017: Arquivos Brasileiros de Cardiologia
https://www.readbyqxmd.com/read/28695455/pcsk9-inhibitors-for-treating-dyslipidemia-in-patients-at-different-cardiovascular-risk-a-systematic-review-and-a-meta-analysis
#5
Alessandro Squizzato, Matteo Basilio Suter, Marta Nerone, Robert Patrick Giugliano, Francesco Dentali, Andrea Maria Maresca, Leonardo Campiotti, Anna Maria Grandi, Luigina Guasti
Statin-induced lowering of low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular morbidity and mortality, but many patients do not adequately reduce their LDL-C levels. Monoclonal antibodies targeting PCKS9 are currently in the advanced phase of development. We aimed to investigate the efficacy and safety of PCSK9 inhibitors in patients at different cardiovascular risk in a systematic review. Studies were searched on MEDLINE and EMBASE until January 2016. Differences in the outcomes among groups were expressed as mean differences, or pooled odds ratio (OR) and corresponding 95% confidence interval (CI), which were calculated using a fixed-effects and a random-effects model...
July 10, 2017: Internal and Emergency Medicine
https://www.readbyqxmd.com/read/28689987/risk-factors-associated-with-atherogenic-dyslipidemia-in-the-presence-of-optimal-statin-therapy
#6
Wang Zhao, Xi-Long Zheng, Ze-Nan Jiang, Xiao-Bo Liao, Shui-Ping Zhao
BACKGROUND: This study investigated the prevalence of atherogenic dyslipidemia (AD) in Chinese outpatients whose low-density lipoprotein cholesterol (LDL-C) levels reached the goals with statin monotherapy and evaluated the characteristics of these patients. METHODS: An analysis of the Dyslipidemia International Survey-China study that was carried out at 122 hospitals in China. Among patients reaching their LDL-C goals, the presence of AD was defined as triglyceride levels ≥1...
June 30, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28685516/comparison-between-atorvastatin-and-rosuvastatin-in-renal-function-decline-among-patients-with-diabetes
#7
Eugene Han, Gyuri Kim, Ji Yeon Lee, Yong Ho Lee, Beom Seok Kim, Byung Wan Lee, Bong Soo Cha, Eun Seok Kang
BACKGROUND: Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes. METHODS: We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treated with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day)...
June 2017: Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28676012/statins-and-the-brain-more-than-lipid-lowering-agents
#8
Anna Fracassi, Martina Marangoni, Pamela Rosso, Valentina Pallottini, Marco Fioramonti, Silvia Siteni, Marco Segatto
BACKGROUND: Statins represent a class of medications widely prescribed to efficiently treat dyslipidemia. These drugs inhibit 3-βhydroxy 3β-methylglutaryl Coenzyme A reductase (HMGR), the rate-limiting enzyme of mevalonate (MVA) pathway. Besides cholesterol, MVA pathway leads to the production of several other compounds, which are essential in the regulation of a plethora of biological activities, including in the central nervous system. For these reasons, statins are able to induce pleiotropic actions, and acquired increased interest as potential and novel modulators in brain processes, especially during pathological conditions...
July 3, 2017: Current Neuropharmacology
https://www.readbyqxmd.com/read/28673294/lipid-management-in-india-a-nationwide-cross-sectional-physician-survey
#9
Gurpreet S Wander, Uday M Jadhav, Amruta Chemburkar, Meena Lopez, Jaideep Gogtay
BACKGROUND: Current international guidelines on dyslipidemia are not concordant on various aspects of management. Also, there are no uniformly accepted Indian guidelines. We, therefore, performed a physician survey to understand lipid management practices in India. METHODS: An anonymous survey questionnaire was administered to gauge physicians' self-reported behavior regarding lipid management aspects. Results were expressed in terms of percentages based on the number of responses obtained...
July 3, 2017: Lipids in Health and Disease
https://www.readbyqxmd.com/read/28672099/impact-of-pharmacogenetics-on-efficacy-and-safety-of-statin-therapy-for-dyslipidemia
#10
Whitney D Maxwell, Laura B Ramsey, Samuel G Johnson, Kate G Moore, Misha Shtutman, John H Schoonover, Marina Kawaguchi-Suzuki
Interindividual variability in response to 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, with regard to both efficacy and safety is an obvious target for pharmacogenetic research. Many genes have been identified as possible contributors to variability in statin response and safety. Genetic polymorphisms may alter the structure or expression of coded proteins, with potential impacts on lipid and statin absorption, distribution, metabolism, and elimination as well as response pathways related to the pharmacologic effect...
July 3, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28669685/association-of-serum-lipid-levels-over-time-with-survival-in-incident-peritoneal-dialysis-patients
#11
Cheol Ho Park, Ea Wha Kang, Jung Tak Park, Seung Hyeok Han, Tae-Hyun Yoo, Shin-Wook Kang, Tae Ik Chang
BACKGROUND: The association of dyslipidemia with mortality has not been fully evaluated in patients on peritoneal dialysis (PD). Moreover, changes in lipids levels over time and associated death risk have not yet been studied in this population. OBJECTIVE: We studied the association of time-updated serum lipid concentrations with all-cause and cardiovascular (CV) mortalities in a 10-year cohort of 749 incident PD patients. METHODS: Association was assessed using time-varying Cox proportional hazard regression models with adjustment for multiple variables including statin therapy...
June 13, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28664622/subclinical-atherosclerosis-in-low-framingham-risk-hiv-patients
#12
Rafael León, Sergio Reus, Nicolás López, Irene Portilla, José Sánchez-Payá, Livia Giner, Vicente Boix, Esperanza Merino, Diego Torrús, Óscar Moreno, Joaquín Portilla
BACKGROUND: Pathogenesis of atherosclerosis is complex and differences between HIV-infected patients and general population cannot be completely explained by the higher prevalence of traditional cardiovascular risk factors. We aimed to analyse the association between inflammation and subclinical atherosclerosis in HIV patients with low Framingham risk score. MATERIALS AND METHODS: Case-control study. SETTING: outpatient Infectious Diseases clinic in a university hospital...
June 29, 2017: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/28655522/preventive-effect-of-pravastatin-on-the-development-of-hypertension-in-patients-with-hypercholesterolemia-a-post-hoc-analysis-of-the-management-of-elevated-cholesterol-in-the-primary-prevention-group-of-adult-japanese-mega-study
#13
Toshiaki Otsuka, Kyoichi Mizuno, Tomohiro Shinozaki, Yuko Kachi, Haruo Nakamura
BACKGROUND: It remains unclear whether treatment of dyslipidemia with 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) reduces the risk of developing hypertension. OBJECTIVE: In this post-hoc analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study, a large-scale primary prevention trial with pravastatin, we examined the preventive effect of pravastatin on the future development of hypertension in patients with hypercholesterolemia...
June 6, 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28644038/critical-review-on-the-analytical-techniques-for-the-determination-of-the-oldest-statin-atorvastatin-in-bulk-pharmaceutical-formulations-and-biological-fluids
#14
K S Kokilambigai, R Seetharaman, K S Lakshmi
Statins are a group of medicines that can help to lower the level of low-density-lipoprotein(LDL) cholesterol "bad cholesterol" in the blood. Having a high level of LDL cholesterol is potentially dangerous, as it can lead to a hardening and narrowing of arteries (atherosclerosis) and cardiovascular disease (CVD), Atorvastatin is one of the oldest member of the statin family and is used in the treatment of dyslipidemia and the prevention of cardiovascular disease. Atorvastatin was first made in August 1985 and from 1996 to 2012 under the trade name Lipitor, atorvastatin became the world's best selling drug...
June 23, 2017: Critical Reviews in Analytical Chemistry
https://www.readbyqxmd.com/read/28635327/within-visit-blood-pressure-variability-and-cardiovascular-risk-factors-in-hypertensive-patients-with-non-dialysis-chronic-kidney-disease
#15
Kengo Azushima, Hiromichi Wakui, Kazushi Uneda, Sona Haku, Ryu Kobayashi, Kohji Ohki, Sho Kinguchi, Kotaro Haruhara, Tetsuya Fujikawa, Yoshiyuki Toya, Satoshi Umemura, Kouichi Tamura
As there may be an association between within-visit blood pressure (BP) variability and cardiovascular disease (CVD), we investigated the clinical significance of this BP variability in non-dialysis chronic kidney disease (CKD) patients. MATERIALS AND METHODS: According to the median of coefficient of variation (CV) of three systolic BP (SBP) readings within a single visit, we divided hypertensive patients with stage G1-4 CKD already treated with antihypertensive therapy into the high SBP-CV group and the low SBP-CV group...
June 21, 2017: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/28622547/co-morbidity-and-clinically-significant-interactions-between-antiepileptic-drugs-and-other-drugs-in-elderly-patients-with-newly-diagnosed-epilepsy
#16
Emmi Bruun, Lauri J Virta, Reetta Kälviäinen, Tapani Keränen
PURPOSE: A study was conducted to investigate the frequency of potential pharmacokinetic drug-to-drug interactions in elderly patients with newly diagnosed epilepsy. We also investigated co-morbid conditions associated with epilepsy. METHOD: From the register of Kuopio University Hospital (KUH) we identified community-dwelling patients aged 65 or above with newly diagnosed epilepsy and in whom use of the first individual antiepileptic drug (AED) began in 2000-2013 (n=529)...
June 13, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28621499/dyslipidemia-in-patients-with-androgenetic-alopecia-statins-finasteride-or-both
#17
L Rudnicka, A Rakowska
No abstract text is available yet for this article.
June 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28573499/effectiveness-of-lipid-lowering-statin-therapy-in-patients-with-and-without-psoriasis
#18
William C Ports, Rana Fayyad, David A DeMicco, Rachel Laskey, Robert Wolk
BACKGROUND: Psoriasis is associated with dyslipidemia and metabolic syndrome, and has been linked to an increased cardiovascular risk. The aim of this study was to compare baseline characteristics and effects of statin therapy on lipid levels and cardiovascular outcomes in patients with and without psoriasis. METHODS: This post-hoc analysis assessed patients from one primary cardiovascular prevention statin trial (Collaborative AtoRvastatin Diabetes Study [CARDS]) and two secondary cardiovascular prevention statin trials (Treating to New Targets [TNT] and Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL])...
August 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28559959/traditional-chinese-medicine-for-lipid-metabolism-disorders
#19
REVIEW
Yiping Li, Xiaolong Wang, Zhijie Shen
Dyslipidemia significantly contributes to the development of cardiovascular disease (CVD), which is the most common cause of morbidity and mortality in China. Statins are the first-line therapy for reducing LDL-C serum levels. However, they have adverse effects, which restrict their clinical application. Traditional Chinese medicine (TCM) preparations have been increasingly described for their beneficial effects in hyperlipidemic patients. Existing data show that the lipid-regulating effects of TCM may be related to: (1) inhibiting intestinal absorption of lipids; (2) reducing endogenous cholesterol synthesis; (3) regulating cholesterol transport; (4) promoting the excretion of cholesterol in the liver; (5) regulating transcription factors related to lipid metabolism...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28545518/design-and-rationale-of-the-odyssey-dm-dyslipidemia-trial-lipid-lowering-efficacy-and-safety-of-alirocumab-in-individuals-with-type-2-diabetes-and-mixed-dyslipidaemia-at-high-cardiovascular-risk
#20
Dirk Müller-Wieland, Lawrence A Leiter, Bertrand Cariou, Alexia Letierce, Helen M Colhoun, Stefano Del Prato, Robert R Henry, Francisco J Tinahones, Lisa Aurand, Jaman Maroni, Kausik K Ray, Maja Bujas-Bobanovic
BACKGROUND: Type 2 diabetes mellitus (T2DM) is often associated with mixed dyslipidaemia, where non-high-density lipoprotein cholesterol (non-HDL-C) levels may more closely align with cardiovascular risk than low-density lipoprotein cholesterol (LDL-C). We describe the design and rationale of the ODYSSEY DM-DYSLIPIDEMIA study that assesses the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, versus lipid-lowering usual care in individuals with T2DM and mixed dyslipidaemia at high cardiovascular risk with non-HDL-C inadequately controlled despite maximally tolerated statin therapy...
May 25, 2017: Cardiovascular Diabetology
keyword
keyword
118412
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"